晚期皮内鳞状细胞癌（aCSCC）是一个无法满足临床需求的领域，直到最近的免疫检查点抑制剂（ICIs）的批准也没有标准化治疗。该研究的目的是描述一组真实意大利aCSCC患者的临床特征和治疗策略，这些患者在意大利批准使用西米替尔回报期初得到管理。10个意大利中心在2018年1月1日至2020年5月31日期间进行了一项多中心回顾性研究，符合以下标准的患者均可参加研究：年龄≥18岁，诊断为aCSCC（局部aCSCC和转移性CSCC）。对患者特征和治疗策略进行分析。最初有239名患者参加了该研究：19名患者由于数据收集不完全而被排除，最终有220名患者被纳入最终组，其中191名和220名患者被纳入患者临床特征和治疗干预分析。诊断时的中位年龄为81岁（范围：72-86岁）；在220名患者中，64名（29％）患者检测到淋巴结转移，33名（15％）患者报道有远处转移扩散。我们的大多数患者均有职业和/或业余日晒曝露，生活中经历过≥1次晒伤，从未戴过帽子或使用过光保护过滤器，并呈现出累积阳光损伤的迹象（太阳斑和/或光化性角化病）。大多数我们的队列接受了至少一种针对原发肿瘤的干预措施（n = 212，96.3％）；手术和放疗是最常见的治疗选择。少数患者在同情使用情况下接受了免疫治疗，尤其是在转移性设置中。我们的研究概述了ICIs时代初期aCSCC患者的复杂和异质性临床和治疗景观，强调对这种脆弱且高需求的患者群体需要标准化护理的需求。©2023S. Karger AG，巴塞尔。

Advanced cutaneous squamous cell carcinoma (aCSCC) represents an area of unmet clinical need, with no standardized treatments until the recent approval of immune checkpoint inhibitors (ICIs).The aim of the study was to describe clinical characteristics and therapeutic strategies of a real-life Italian cohort of aCSCC patients managed at the beginning of cemiplimab approval as compassionate use in Italy.A multicenter retrospective study was performed by 10 Italian centers in the period January 1, 2018-May 31, 2020. Patients aged ≥18 years and diagnosed with aCSCC (locally aCSCC and metastatic CSCC) were eligible for the study. Analysis of patients' characteristics and treatment strategies was performed.239 patients were initially recruited in the study: 19 patients were excluded due to incomplete data collection, yielding a final cohort of 220 patients, of which 191 and 220 were included for patients' clinical characteristics and therapeutic intervention analysis, respectively. Median age at the time of diagnosis was 81 years (range: 72-86); nodal metastases were detected in 64/220 (29%) patients, and distant metastatic spread was reported in 33/220 (15%) patients. Most of our patients referred chronic occupational and/or recreational sun exposure, experienced ≥1 sunburn during their lifetime, never wore hats or used photoprotective filters, and presented with signs of cumulative sun damage (solar lentigines and/or actinic keratosis). Majority of our cohort received at least one intervention directed to the primary tumor (n = 212, 96.3%); surgery and radiotherapy were the most common therapeutic choices. Immunotherapy was administered to a small number of patients as compassionate use, especially in the metastatic setting.Our study outlines the complex and heterogeneous clinical and therapeutic landscape of aCSCC patients at the beginning of ICI era, highlighting the need of a standardized care for this fragile and high-need patient population.© 2023 S. Karger AG, Basel.